Fundamental Analysis of UNIQURE NV(NASDAQ:QURE) stock

Fundamental Rating

QURE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 574 industry peers in the Biotechnology industry. Both the profitability and financial health of QURE have multiple concerns. While showing a medium growth rate, QURE is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year QURE has reported negative net income.

In the past year QURE has reported a negative cash flow from operations.

In the past 5 years QURE reported 4 times negative net income.

In the past 5 years QURE reported 4 times negative operating cash flow.

1.2 Ratios

QURE's Return On Assets of -38.95% is in line compared to the rest of the industry. QURE outperforms 58.27% of its industry peers.

Looking at the Return On Equity, with a value of -293.18%, QURE is doing worse than 75.35% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-38.95%
ROE	-293.18%
ROIC	N/A

ROA(3y)-4.78%

ROA(5y)-15.75%

ROE(3y)-39.95%

ROE(5y)-41.91%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

QURE has a better Gross Margin (4.26%) than 74.12% of its industry peers.

The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	4.26%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for QURE has been increased compared to 1 year ago.

QURE has more shares outstanding than it did 5 years ago.

Compared to 1 year ago, QURE has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -1.90, we must say that QURE is in the distress zone and has some risk of bankruptcy.

QURE has a Altman-Z score (-1.90) which is comparable to the rest of the industry.

A Debt/Equity ratio of 5.34 is on the high side and indicates that QURE has dependencies on debt financing.

QURE has a Debt to Equity ratio of 5.34. This is amonst the worse of the industry: QURE underperforms 83.80% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	5.34
Debt/FCF	N/A
Altman-Z	-1.9

ROIC/WACCN/A

WACC7.97%

2.3 Liquidity

QURE has a Current Ratio of 7.36. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.

QURE's Current ratio of 7.36 is fine compared to the rest of the industry. QURE outperforms 68.49% of its industry peers.

QURE has a Quick Ratio of 7.36. This indicates that QURE is financially healthy and has no problem in meeting its short term obligations.

With a decent Quick ratio value of 7.36, QURE is doing good in the industry, outperforming 68.66% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	7.36
Quick Ratio	7.36

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for QURE have decreased strongly by -50.35% in the last year.

QURE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.22%.

The Revenue has been growing slightly by 6.99% on average over the past years.

EPS 1Y (TTM)-50.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%19.44%

Revenue 1Y (TTM)-75.22%

Revenue growth 3Y-24.96%

Revenue growth 5Y6.99%

Sales Q2Q%359.37%

3.2 Future

Based on estimates for the next years, QURE will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.58% on average per year.

QURE is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 66.81% yearly.

EPS Next Y33.1%

EPS Next 2Y24.99%

EPS Next 3Y17.94%

EPS Next 5Y9.58%

Revenue Next Year114.23%

Revenue Next 2Y80.39%

Revenue Next 3Y74.07%

Revenue Next 5Y66.81%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

QURE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year QURE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as QURE's earnings are expected to grow with 17.94% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y24.99%

EPS Next 3Y17.94%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

QURE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

UNIQURE NV

NASDAQ:QURE (9/6/2024, 8:00:02 PM)

After market: 5.42 0 (0%)

5.42

-0.11 (-1.99%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap263.14M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-38.95%
ROE	-293.18%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	4.26%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.04

Health

		Industry Rank	Sector Rank
Debt/Equity	5.34
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	7.36
Quick Ratio	7.36
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-50.35%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y33.1%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-75.22%

Revenue growth 3Y-24.96%

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

UNIQURE NV (QURE)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens